New York State Common Retirement Fund’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.09M | Buy |
25,243
+6,861
| +37% | +$717K | ﹤0.01% | 1284 |
|
|
2026
Q1 | $1.94M | Hold |
18,382
| – | – | ﹤0.01% | 1398 |
|
|
2025
Q4 | $1.61M | Sell |
18,382
-1,200
| -6% | -$98.2K | ﹤0.01% | 1495 |
|
|
2025
Q3 | $1.3M | Hold |
19,582
| – | – | ﹤0.01% | 1587 |
|
|
2025
Q2 | $1.08M | Hold |
19,582
| – | – | ﹤0.01% | 1636 |
|
|
2025
Q1 | $947K | Buy |
19,582
+1,700
| +10% | +$71.2K | ﹤0.01% | 1652 |
|
|
2024
Q4 | $690K | Sell |
17,882
-2,300
| -11% | -$100K | ﹤0.01% | 1828 |
|
|
2024
Q3 | $908K | Sell |
20,182
-2,900
| -13% | -$117K | ﹤0.01% | 1713 |
|
|
2024
Q2 | $800K | Buy |
23,082
+38
| +0.2% | +$1.11K | ﹤0.01% | 1861 |
|
|
2024
Q1 | $667K | Sell |
23,044
-59
| -0.3% | -$1.6K | ﹤0.01% | 1959 |
|
|
2023
Q4 | $530K | Sell |
23,103
-98
| -0.4% | -$1.72K | ﹤0.01% | 2075 |
|
|
2023
Q3 | $387K | Buy |
23,201
+237
| +1% | +$4.6K | ﹤0.01% | 2156 |
|
|
2023
Q2 | $634K | Sell |
22,964
-4,728
| -17% | -$118K | ﹤0.01% | 1968 |
|
|
2023
Q1 | $637K | Buy |
27,692
+19
| +0.1% | +$319 | ﹤0.01% | 2055 |
|
|
2022
Q4 | $302K | Sell |
27,673
-24
| -0.1% | -$202 | ﹤0.01% | 2550 |
|
|
2022
Q3 | $233K | Buy |
27,697
+5,397
| +24% | +$51.1K | ﹤0.01% | 2708 |
|
|
2022
Q2 | $176K | Sell |
22,300
-10,906
| -33% | -$132K | ﹤0.01% | 2850 |
|
|
2022
Q1 | $786K | Buy |
33,206
+45
| +0.1% | +$1.27K | ﹤0.01% | 2221 |
|
|
2021
Q4 | $1.13M | Buy |
33,161
+3,223
| +11% | +$102K | ﹤0.01% | 2062 |
|
|
2021
Q3 | $531K | Sell |
29,938
-5,852
| -16% | -$249K | ﹤0.01% | 2435 |
|
|
2021
Q2 | $1.61M | Buy |
35,790
+8,290
| +30% | +$274K | ﹤0.01% | 1999 |
|
|
2021
Q1 | $712K | Hold |
27,500
| – | – | ﹤0.01% | 2281 |
|
|
2020
Q4 | $554K | Buy |
27,500
+6,600
| +32% | +$142K | ﹤0.01% | 2306 |
|
|
2020
Q3 | $409K | Hold |
20,900
| – | – | ﹤0.01% | 2308 |
|
|
2020
Q2 | $369K | Buy |
20,900
+5,400
| +35% | +$67.7K | ﹤0.01% | 2368 |
|
|
2020
Q1 | $109K | Hold |
15,500
| – | – | ﹤0.01% | 2739 |
|
|
2019
Q4 | $109K | Hold |
15,500
| – | – | ﹤0.01% | 2980 |
|
|
2019
Q3 | $186K | Hold |
15,500
| – | – | ﹤0.01% | 2808 |
|
|
2019
Q2 | $188K | Buy |
+15,500
| New | +$171K | ﹤0.01% | 2848 |
|
|
2018
Q2 | – | Sell |
-13,600
| Closed | -$117K | – | 3203 |
|
|
2018
Q1 | $117K | Buy |
13,600
+3,400
| +33% | +$64K | ﹤0.01% | 2923 |
|
|
2017
Q4 | $212K | Buy |
10,200
+2,600
| +34% | +$46.1K | ﹤0.01% | 2734 |
|
|
2017
Q3 | $134K | Hold |
7,600
| – | – | ﹤0.01% | 2935 |
|
|
2017
Q2 | $86K | Sell |
7,600
-1
| -0% | -$11 | ﹤0.01% | 3107 |
|
|
2017
Q1 | $97K | Buy |
+7,601
| New | +$122K | ﹤0.01% | 2974 |
|
Other funds holding PTGX
FCM
RI
JJ
New York State Common Retirement Fund's PTGX Position: Q2 2026 in Review
New York State Common Retirement Fund increased its Protagonist Therapeutics (PTGX) stake by 37% in Q2 2026, buying an estimated $717K and bringing the position to 25,243 shares worth $3.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1284.
New York State Common Retirement Fund first reported a position in PTGX in Q1 2017 and has held it in 34 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.
- New York State Common Retirement Fund held 25,243 shares of Protagonist Therapeutics worth $3.09M as of Q2 2026.
- New York State Common Retirement Fund bought 6,861 Protagonist Therapeutics shares in Q2 2026, an estimated $717K.
- Protagonist Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1284 holding.
- New York State Common Retirement Fund first reported a position in Protagonist Therapeutics in Q1 2017 and has held it in 34 quarters since.
- 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.